Allergy Therapeutics’ VLP Peanut Trial: A Potential Game-Changer for Peanut Allergy Treatment

Allergy Therapeutics ((GB:AGY)) announced an update on their ongoing clinical study.

Allergy Therapeutics is conducting a Phase I clinical trial titled ‘A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT).’ The study aims to assess the safety, tolerability, and preliminary efficacy of VLP Peanut, a potential treatment for peanut allergies. This trial is significant as it could lead to a new therapeutic option for individuals with peanut allergies, a condition with limited treatment options.

The intervention being tested is VLP Peanut, a biological solution administered subcutaneously or through skin-prick testing. Its purpose is to evaluate its safety and potential effectiveness in reducing allergic reactions in individuals with peanut allergies.

The study design involves a randomized, sequential intervention model with two parts. Part A is open-label, involving healthy and peanut-allergic subjects, while Part B is a double-blind, placebo-controlled trial for peanut-allergic subjects. The primary purpose is treatment, with masking applied to participants, care providers, investigators, and outcomes assessors in Part B.

The study began on July 8, 2022, with its primary completion and estimated completion dates not yet specified. The last update was submitted on August 11, 2025, indicating ongoing progress and adjustments to the study.

This update could positively impact Allergy Therapeutics’ stock performance and investor sentiment, as successful results may lead to a new marketable treatment for peanut allergies. Competitors in the allergy treatment space will likely monitor these developments closely.

The study is ongoing, with further details available on the ClinicalTrials portal.